Motif Bio plc: Notice of Annual General Meeting
April 26 2019 - 2:01AM
Motif Bio plc ("Motif Bio" or the "Company") (AIM/NASDAQ: MTFB), a
clinical-stage biopharmaceutical company specialising in developing
novel antibiotics, today announced that its notice of its Annual
General Meeting (AGM) have been posted to shareholders and will
shortly be available for download from the Company's website at
www.motifbio.com.
This follows the announcement made by the
Company on 15 April 2019 via RNS of the publication of its
financial results for the year ended 31 December 2018 and the
filing of its U.S. Annual Report on Form 20-F with the U.S.
Securities and Exchange Commission.
The Company's AGM is to be held at 1 PM BST on
22 May 2019 at the offices of DLA Piper UK LLP at 160 Aldersgate
Street London EC1A 4HT, United Kingdom. The Notice of the AGM and
Proxy Form for General Meeting will be available later today on the
Investors section of the Company’s website at www.motifbio.com.
|
|
|
For further information
please contact: |
|
|
|
|
|
Motif Bio
plc |
|
info@motifbio.com |
Graham Lumsden (Chief
Executive Officer) |
|
|
|
|
|
Peel Hunt LLP
(NOMAD & JOINT BROKER) |
|
+44 (0)20 7418
8900 |
Dr Christopher
Golden |
|
|
Oliver Jackson |
|
|
|
|
|
SP ANGEL
CORPORATE FINANCE LLP |
|
|
(JOINT
BROKER) |
|
+44 (0)20 3470
0470 |
David Hignell |
|
|
Vadim Alexandre |
|
|
Rob Rees |
|
|
|
|
|
Walbrook PR
Ltd. (UK FINANCIAL PR & IR) |
|
+44 (0) 20 7933
8780 |
Paul McManus/Helen
Cresswell/Lianne Cawthorne |
|
|
|
|
|
MC Services AG
(EUROPEAN IR) |
|
+49 (0)89 210 2280 |
Raimund Gabriel |
|
raimund.gabriel@mc-services.eu |
|
|
|
Russo Partners
(U.S. PR) |
|
+1 (858) 717-2310 or +1
(212) 845 4272 |
David Schull |
|
david.schull@russopartnersllc.com |
|
|
|
Note to Editors
Motif Bio plc (AIM/NASDAQ: MTFB) is a
clinical-stage biopharmaceutical company focused on developing
novel antibiotics designed to be effective against serious and
life-threatening infections caused by multi-drug resistant
Gram-positive bacteria, including MRSA. The Company's lead product
candidate is iclaprim. Motif Bio is seeking approval of iclaprim
from the U.S. Food & Drug Administration (FDA) for the
treatment of acute bacterial skin and skin structure infections
(ABSSSI). More than 3.6 million patients with ABSSSI are
hospitalised annually in the U.S. It is estimated that up to 26% of
hospitalized ABSSSI patients have renal impairment.
The Company also has plans to develop iclaprim
for hospital acquired bacterial pneumonia (HABP), including
ventilator associated bacterial pneumonia (VABP), as there is a
high unmet need for new therapies in this indication. A Phase 2
trial in patients with HABP has been successfully completed and a
Phase 3 trial is being planned. Additionally, iclaprim has been
granted orphan drug designation by the FDA for the treatment of
Staphylococcus aureus lung infections in patients with cystic
fibrosis and is in preclinical development for this indication.
Iclaprim has received Qualified Infectious
Disease Product (QIDP) designation from the FDA together with Fast
Track status for the ABSSSI indication. If approved for the ABSSSI
indication as a New Chemical Entity, iclaprim will be eligible for
10 years of market exclusivity in the U.S. from the date of first
approval, under the Generating Antibiotic Incentives Now Act (the
GAIN Act). In Europe, 10 years of market exclusivity is
anticipated. Motif is also building a patent estate to provide
additional protection for iclaprim and has two U.S. method of use
patents issued that will expire in 2037.
Forward-Looking StatementsThis release contains
forward-looking statements. Words such as "expect," "believe,"
"intend," "plan," "continue," "may," "will," "anticipate," and
similar expressions are intended to identify forward-looking
statements. Forward-looking statements involve known and unknown
risks, uncertainties and other important factors that may cause
Motif Bio's actual results, performance or achievements to be
materially different from any future results, performance or
achievements expressed or implied by the forward-looking
statements. Motif Bio believes that these factors include, but are
not limited to, (i) the timing, progress and the results of
clinical trials for Motif Bio's product candidates, (ii) the
timing, scope or likelihood of regulatory filings and approvals for
Motif Bio's product candidates, (iii) Motif Bio's ability to
successfully commercialise its product candidates, (iv) Motif Bio's
ability to effectively market any product candidates that receive
regulatory approval, (v) Motif Bio's commercialisation, marketing
and manufacturing capabilities and strategy, (vi) Motif Bio's
expectation regarding the safety and efficacy of its product
candidates, (vii) the potential clinical utility and benefits of
Motif Bio's product candidates, (viii) Motif Bio's ability to
advance its product candidates through various stages of
development, especially through pivotal safety and efficacy trials,
(ix) Motif Bio's estimates regarding the potential market
opportunity for its product candidates, (x) Motif Bio's ability to
raise additional capital to sustain its operations and pursue its
strategy and (xi) the factors discussed in the section entitled
"Risk Factors" in Motif Bio's Annual Report on Form 20-F filed with
the SEC on April 15, 2019, which is available on the SEC's web
site, www.sec.gov. Motif Bio undertakes no obligation to update or
revise any forward-looking statements.
Motif Bio (NASDAQ:MTFB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Motif Bio (NASDAQ:MTFB)
Historical Stock Chart
From Apr 2023 to Apr 2024